Mastocytosis News and Research

RSS

NCCN publishes new resources for treating rare tumor types

The National Comprehensive Cancer Network-;an alliance of leading cancer centers-;today announced the publication of new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ampullary Adenocarcinoma.

9 Mar 2022

Activated mast cell disorders potentially linked to SARS-CoV-2 immunity

An intriguing new study reports a year-long study in patients with cMCADs from all over France.

7 Sep 2021

Potential new treatment for mast cell cancers reduces tumor size and prevents organ infiltration

A potential new treatment for mast cell cancers reduces the number of mast cells by "mutating" the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.

10 Aug 2021

People with venom allergies are more likely to have bone marrow disorder

Researchers at Michigan Medicine found that people with venom allergies are much more likely to suffer mastocytosis, a bone marrow disorder that causes higher risk of fatal reactions.

19 May 2021

New taxonomic classification of non-skeletal rare congenital disorders with impact on bone physiology

Thanks to major progress in the understanding and management of rare congenital diseases and syndromes, many patients with these rare disorders are now living longer lives.

13 Jan 2021

Researchers detect a novel cause of acquired lipodystrophy

Nonalcoholic fatty liver disease (NAFLD) is mostly diagnosed in overweight and obese people. However, severe forms of NAFLD can also be detected in rare genetic diseases such as lipodystrophy or in patients with HIV, putting them at a high risk for developing liver failure, diabetes and cardiovascular diseases.

3 Mar 2020

Leukemia is not just one disease

An estimated 61,780 new cases of leukemia will be diagnosed in the United States this year, with some 2,000 cases in New Jersey, according to the American Cancer Society.

30 Aug 2019

Researchers map genetic mutation behind incurable disease

Researchers at Karolinska Institutet have mapped the genetic mutation behind the incurable disease systemic mastocytosis.

10 Apr 2019

Researchers design new combination therapy for reducing NSCLC cell growth

Lung cancer is the leading cause of cancer death among men and women. About 85 percent of lung cancers are non-small cell lung cancer. For a handful of these patients, therapies that target specific genetic mutations are effective.

29 Sep 2018

Inexplicable cases of anaphylaxis caused by uncommon red meat allergy, study finds

While rare, some people experience recurrent episodes of anaphylaxis--a life-threatening allergic reaction that causes symptoms such as the constriction of airways and a dangerous drop in blood pressure--for which the triggers are never identified.

28 Nov 2017

Study provides new insight into development of immune cells

In contrast to what has been previously believed, development of blood stem cells to mast cells, a type of specialized immune cell, does not depend on a growth factor called stem cell factor.

10 Aug 2017

FDA approves new drug and chemotherapy combination for treatment of adult patients with AML

The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have a specific genetic mutation called FLT3, in combination with chemotherapy.

28 Apr 2017

New drug holds potential for treating advanced mastocytosis

Most people have never heard of mastocytosis. It's a rare, sometimes deadly, immune disorder. Now new research may help those with advanced mastocytosis and possibly many more people, too.

6 Sep 2016

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

New cell type appears to drive life-threatening food allergies

Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.

22 Sep 2015

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).

13 Jul 2015

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets.

11 May 2015

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13.

2 Dec 2014

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Complex process of bone disease evident in mastocytosis

Patients with mastocytosis show elevated bone turnover that is associated with a higher mast cell load and advanced disease relative to individuals without the condition, suggest study findings.

12 Dec 2012